SuperworthMyomo MYO
- Market cap
- $47.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $43.3M
- +6% on a year ago
- Net margin
- −33.5%
- Free cash flow yield
- −15.2%
Myomo trades at 1.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $43.3M over the last twelve months, up 6% on a year earlier with a −34% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.1M+28% | $4.8M+18% | $3.8M+9% | $7.5M+26% | $9.2M+81% | $12.1M+154% | $9.8M+162% | $9.7M+28% | $10.1M+10% | $11.4M−6% | $10.1M+3% | $11.7M+21% | |
| Cost of revenue | $1.6M+20% | $1.7M+17% | $1.5M+28% | $2.2M+31% | $2.3M+42% | $3.5M+109% | $3.2M+121% | $3.6M+64% | $3.6M+61% | $3.6M+3% | $3.2M−0% | $3.3M−9% |
| Gross profit | $3.5M+32% | $3.1M+18% | $2.3M−0% | $5.3M+24% | $6.9M+99% | $8.6M+178% | $6.6M+188% | $6.1M+14% | $6.4M−7% | $7.8M−10% | $6.9M+4% | $8.4M+40% |
| R&D | $717.3K+4% | $878K+76% | $956.2K+101% | $1M+79% | $1.2M+74% | $1.6M+78% | $1.8M+87% | $2M+99% | $1.5M+22% | $1.6M+4% | $1.6M−9% | $1.7M−14% |
| SG&A | $4.8M+1% | $4.7M+7% | $5.2M+16% | $5.4M+13% | $6.7M+39% | $7.3M+57% | $8.3M+59% | $8.6M+59% | $8.4M+27% | $8.9M+22% | $8.4M+1% | $9M+4% |
| −$2M−28% | −$2.4M+9% | −$3.9M+46% | −$1.1M+1% | −$957.6K−53% | −$245.3K−90% | −$3.5M−10% | −$4.6M+312% | −$3.5M+267% | −$2.8M+1031% | −$3.2M−10% | −$2.3M−51% | |
| Interest expense | n/a | n/a | n/a | n/a | −$76K | n/a | −$192K | −$106.5K | $9.7K | n/a | $504.7K | $535.7K |
| Pre-tax income | −$2M−29% | −$2.4M+9% | −$3.8M+44% | −$1M−1% | −$881.5K−56% | −$175.3K−93% | −$3.3M−11% | −$4.5M+345% | −$3.5M+300% | −$3.7M+2028% | −$2.8M−15% | −$4M−11% |
| $46.4K+98% | $70.8K | $82.2K+94% | $113.8K | $84.9K+83% | $84.8K+20% | $136.8K+67% | $148.2K+30% | $135.7K+60% | $83.9K−1% | $186.7K+37% | $31.4K−79% | |
| Net income | −$2M−28% | −$2.5M+14% | −$3.8M+45% | −$1.1M+11% | −$966.4K−52% | −$260.1K−89% | −$3.5M−10% | −$4.6M+313% | −$3.7M+279% | −$3.8M+1366% | −$3M−13% | −$4M−13% |
| −$0.06−85% | −$0.07−76% | −$0.10−9% | −$0.03−25% | −$0.03−50% | −$0.01−86% | −$0.08−20% | −$0.11+267% | −$0.09+200% | −$0.09+800% | −$0.07−13% | −$0.09−18% | |
| 35.3M+399% | 35.3M+367% | 36.8M+52% | 37.4M+34% | 38M+8% | 38.9M+10% | 41.5M+13% | 41.6M+11% | 42.2M+11% | 42.2M+8% | 42.3M+2% | 42.7M+3% |
Revenue: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
R&D: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
SG&A: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Operating income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 12 periods, Q1 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY16: share-days: the 6-month average less the second quarter's. 10 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Myomo's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MYOMyomo | $47.9M | n/m | n/a | 1.1× | +6% | −33.5% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| Peer median | $199.3M | 15.1× | 16.6× | 1.9× | +5% | 8.4% |
More on Myomo
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .